Legend Biotech Corp ADR (NASDAQ:LEGN)’s traded shares stood at 1.1 million during the last session, with the company’s beta value hitting 0.10. At the close of trading, the stock’s price was $44.74, to imply an increase of 1.54% or $0.68 in intraday trading. The LEGN share’s 52-week high remains $70.13, putting it -56.75% down since that peak but still an impressive 13.72% since price per share fell to its 52-week low of $38.60. The company has a valuation of $8.20B, with an average of 1.97 million shares in intraday trading volume over the past 10 days and average of 983.97K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Legend Biotech Corp ADR (LEGN), translating to a mean rating of 1.25. Of 11 analyst(s) looking at the stock, 0 analyst(s) give LEGN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 11 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
After registering a 1.54% upside in the last session, Legend Biotech Corp ADR (LEGN) has traded red over the past five days. The 5-day price performance for the stock is 4.36%, and -4.50% over 30 days. With these gigs, the year-to-date price performance is -25.64%. Short interest in Legend Biotech Corp ADR (NASDAQ:LEGN) saw shorts transact 12.07 million shares and set a 12.36 days time to cover.
The extremes give us $60 and $94 for target low and target high price respectively. As such, LEGN has been trading -110.1% off suggested target high and -34.11% from its likely low.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Looking at statistics comparing Legend Biotech Corp ADR share performance against respective industry, we note that the company has underperformed competitors. Legend Biotech Corp ADR (LEGN) shares are -1.24% down over the last 6 months, with its year-to-date growth rate lower than industry average at -0.68% against 17.50%. Revenue is forecast to shrink -23.50% this quarter before jumping 57.50% for the next one. The rating firms project that company’s revenue will grow 105.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 14 analysts is 142.84M. Meanwhile, for the current quarter, a total of 14 analyst(s) estimate revenue growth to 176.93M.Earnings reports from the last fiscal year show that sales brought in 96.01M and 79.46M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 48.80% before jumping 122.70% in the following quarter.
LEGN Dividends
Legend Biotech Corp ADR has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is PRICE T ROWE ASSOCIATES INC /MD/ with 11.49 million shares, or about 6.3126% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $508.86 million.
We also have Fidelity Select Portfolios – Health Care and Price (T.Rowe) Growth Stock Fund Inc. as the top two Mutual Funds with the largest holdings of the Legend Biotech Corp ADR (LEGN) shares. Going by data provided on Aug 31, 2024 , Fidelity Select Portfolios – Health Care holds roughly 2.5 shares. This is just over 1.37% of the total shares, with a market valuation of $111.85 million. Data from the same date shows that the other fund manager holds a little less at 2.4, or 1.32% of the shares, all valued at about 107.34 million.
